Dr. Mooradian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Deaconess 31
Boston, MA 02114Phone+1 617-724-4000
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2013 - 2017
- Beth Israel Deaconess Medical CenterChief Residency, Internal Medicine, 2015 - 2016
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2010 - 2013
- Boston University School of MedicineClass of 2010
Certifications & Licensure
- MA State Medical License 2013 - 2025
- NH State Medical License 2021 - 2025
- ME State Medical License 2021 - 2022
- RI State Medical License 2021 - 2022
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Rising Star in Oncology STOFF, 2016
- Chief Medical Officer BIDMC, 2014
Clinical Trials
- Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma Start of enrollment: 2020 Jun 12
- Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy Start of enrollment: 2018 Jan 17
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Start of enrollment: 2019 Jun 12
Publications & Presentations
PubMed
- 782 citationsThe Effect of Advances in Lung-Cancer Treatment on Population MortalityNadia Howlader, Gonçalo Forjaz, Meghan J. Mooradian, Rafael Meza, Chung Yin Kong
The New England Journal of Medicine. 2020-08-12 - 30 citationsReal-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.Bruce C Tiu, Leyre Zubiri, James Iheke, Vartan Pahalyants, Nicholas Theodosakis
Journal for Immunotherapy of Cancer. 2022-06-01 - 175 citationsThe Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.Harish Seethapathy, Sophia Zhao, Donald F. Chute, Leyre Zubiri, Yaa Oppong
Clinical Journal of the American Society of Nephrology. 2019-12-06
Journal Articles
- Differential Expression of PD-L1 and IDO1 in Association with the Immune Microenvironment in Resected Lung AdenocarcinomasM Lisa Zhang, Justin F Gainor, Meghan J Mooradian, Nature
- Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.Meghan Campo, Hani Al-Halabi, Melin Khandekar, Alice T Shaw, Lecia V Sequist, Henning Willers, Oncologist, 6/27/2016
- Hemophagocytic Lymphohistiocytosis in Adults.Meghan Campo, Nancy Berliner, Hematol. Oncol. Clin. North Am., 10/2015
- Join now to see all
Authored Content
- Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
- Corrigendum to “Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study*” [Eur J Cancer 91 (2018) 116–124]March 2018
- Rechallenge with BRAF-Directed Treatment in Metastatic Melanoma: A Multi-Institutional Retrospective Study☆February 2018
Press Mentions
- After Practice Change in Unresectable Stage III NSCLC, Questions RemainSeptember 4th, 2024
Grant Support
- T32DFCI/HCC2015–2017
Professional Memberships
- Member
- American Society of Clinical OncologyMember
- Society of Melanoma ResearchMember
- Society for Immunotherapy of CancerMember
- International association for the study of lung cancer (IASLC)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: